{"classes":[{"categories":[{"measurements":[{"comment":"Not estimable/calculable due to low number of participants with events","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"9.7"},{"comment":"Not estimable/calculable due to low number of participants with events","groupId":"OG002","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"groupId":"OG004","lowerLimit":"7.8","upperLimit":"27.0","value":"17.3"},{"groupId":"OG005","lowerLimit":"5.7","upperLimit":"21.9","value":"13.1"},{"groupId":"OG006","lowerLimit":"7.6","upperLimit":"28.8","value":"17.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"13"},{"groupId":"OG005","value":"13"},{"groupId":"OG006","value":"15"}],"units":"Participants"}],"description":"DOR is defined as the number of days from the date of first response of Partial Response (PR) or better to the date of first documented disease progression or death due to multiple myeloma, whichever occurs first. DOR was analyzed by Kaplan- Meier (K-M) methodology.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants in the dose-escalation cohort received 300 mg of venetoclax daily on Days 1 -21 of each cycle after a 2-week lead-in period, during which venetoclax doses were increased weekly.","id":"OG000","title":"Phase 1: Venetoclax 300 mg"},{"description":"Participants in the dose-escalation cohort received 600 mg of venetoclax daily on Days 1 -21 of each cycle after a 2-week lead-in period, during which venetoclax doses were increased weekly.","id":"OG001","title":"Phase 1: Venetoclax 600 mg"},{"description":"Participants in the dose-escalation cohort received 900 mg of venetoclax daily on Days 1 -21 of each cycle after a 2-week lead-in period, during which venetoclax doses were increased weekly.","id":"OG002","title":"Phase 1: Venetoclax 900 mg"},{"description":"Participants in the dose-escalation cohort received 1200 mg of venetoclax daily on Days 1 -21 of each cycle after a 2-week lead-in period, during which venetoclax doses were increased weekly.","id":"OG003","title":"Phase 1: Venetoclax 1200 mg"},{"description":"Participants in the safety expansion cohort received 1200 mg of venetoclax daily on Days 1 - 21 of each cycle after a 2-week lead-in period, during which venetoclax doses were increased weekly.","id":"OG004","title":"Phase 1 Safety Expansion: Venetoclax 1200 mg"},{"description":"Participants with t(11;14) translocation multiple myeloma received daily venetoclax at a dose of 800 mg (no lead-in period) on Days 1- 21 of each cycle concomitant with weekly dexamethasone at a dose of 40 mg (20 mg for those aged ≥ 75 years).","id":"OG005","title":"Phase 1 Combination: Venetoclax 800 mg/Dexamethasone 20 or 40 mg"},{"description":"The Phase 2 cohort further explored the efficacy of venetoclax in combination with dexamethasone in relapsed or refractory participants with t(11;14) translocation multiple myeloma. Participants received daily venetoclax at a dose of 800 mg (no lead-in period) on Days 1- 21 of each cycle concomitant with weekly dexamethasone at a dose of 40 mg (20 mg for those aged ≥ 75 years).","id":"OG006","title":"Phase 2 Expansion: Venetoclax 800 mg/Dexamethasone 20 or 40 mg"}],"paramType":"MEDIAN","populationDescription":"All enrolled participants who received venetoclax, had active disease at baseline, and achieved a response of PR or better","reportingStatus":"POSTED","timeFrame":"Assessed at Cycle 2, Day 1, and on Day 1 of every cycle thereafter; estimated median duration of follow-up was 8.1 months for Phase 1 and 31.7 months for Phase 2","title":"Duration of Response","type":"SECONDARY","unitOfMeasure":"months"}